
## Rajal B Shah

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7573834/publications.pdf Version: 2024-02-01



**Ρ**ΛΙΛΙ Β <u></u>

#	Article	IF	CITATIONS
1	Recurrent Fusion of <i>TMPRSS2</i> and ETS Transcription Factor Genes in Prostate Cancer. Science, 2005, 310, 644-648.	12.6	3,541
2	Delineation of prognostic biomarkers in prostate cancer. Nature, 2001, 412, 822-826.	27.8	1,551
3	Integrative molecular concept modeling of prostate cancer progression. Nature Genetics, 2007, 39, 41-51.	21.4	837
4	Androgen-Independent Prostate Cancer Is a Heterogeneous Group of Diseases. Cancer Research, 2004, 64, 9209-9216.	0.9	816
5	Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature, 2007, 448, 595-599.	27.8	743
6	Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell, 2005, 8, 393-406.	16.8	731
7	Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 3933-3938.	7.1	641
8	Role of the TMPRSS2-ERG Gene Fusion in Prostate Cancer. Neoplasia, 2008, 10, 177-IN9.	5.3	608
9	TMPRSS2:ETV4 Gene Fusions Define a Third Molecular Subtype of Prostate Cancer. Cancer Research, 2006, 66, 3396-3400.	0.9	432
10	A Polycomb Repression Signature in Metastatic Prostate Cancer Predicts Cancer Outcome. Cancer Research, 2007, 67, 10657-10663.	0.9	308
11	The Role of SPINK1 in ETS Rearrangement-Negative Prostate Cancers. Cancer Cell, 2008, 13, 519-528.	16.8	303
12	Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer. Modern Pathology, 2007, 20, 538-544.	5.5	281
13	Clear Cell Papillary Renal Cell Carcinoma. American Journal of Surgical Pathology, 2008, 32, 1239-1245.	3.7	252
14	Characterization of <i>TMPRSS2</i> -ETS Gene Aberrations in Androgen-Independent Metastatic Prostate Cancer. Cancer Research, 2008, 68, 3584-3590.	0.9	249
15	Noninvasive Detection of TMPRSS2:ERG Fusion Transcripts in the Urine of Men with Prostate Cancer. Neoplasia, 2006, 8, 885-888.	5.3	212
16	Fluorescence in situ hybridization study shows association of PTEN deletion with ERG rearrangement during prostate cancer progression. Modern Pathology, 2009, 22, 1083-1093.	5.5	209
17	Prevalence of <i>TMPRSS2-ERG</i> Fusion Prostate Cancer among Men Undergoing Prostate Biopsy in the United States. Clinical Cancer Research, 2009, 15, 4706-4711.	7.0	205
18	Integrative Genomics Analysis Reveals Silencing of β-Adrenergic Signaling by Polycomb in Prostate Cancer. Cancer Cell, 2007, 12, 419-431.	16.8	204

#	Article	IF	CITATIONS
19	Characterization of <i>TMPRSS2-ERG</i> Fusion High-Grade Prostatic Intraepithelial Neoplasia and Potential Clinical Implications. Clinical Cancer Research, 2008, 14, 3380-3385.	7.0	200
20	Metastasis suppressor gene Raf kinase inhibitor protein (RKIP) is a novel prognostic marker in prostate cancer. Prostate, 2006, 66, 248-256.	2.3	197
21	Heterogeneity of <i>TMPRSS2</i> Gene Rearrangements in Multifocal Prostate Adenocarcinoma: Molecular Evidence for an Independent Group of Diseases. Cancer Research, 2007, 67, 7991-7995.	0.9	197
22	MDCT Urography of Upper Tract Urothelial Neoplasms. American Journal of Roentgenology, 2005, 184, 1873-1881.	2.2	184
23	Comparison of the Basal Cell-Specific Markers, 34βE12 and p63, in the Diagnosis of Prostate Cancer. American Journal of Surgical Pathology, 2002, 26, 1161-1168.	3.7	175
24	Tubulocystic Carcinoma of the Kidney. American Journal of Surgical Pathology, 2008, 32, 177-187.	3.7	156
25	The 2019 Genitourinary Pathology Society (GUPS) White Paper on Contemporary Grading of Prostate Cancer. Archives of Pathology and Laboratory Medicine, 2021, 145, 461-493.	2.5	143
26	Basal Cell Cocktail (34βE12 + p63) Improves the Detection of Prostate Basal Cells. American Journal of Surgical Pathology, 2003, 27, 365-371.	3.7	141
27	A Fluorescence <i>In situ</i> Hybridization Screen for E26 Transformation–Specific Aberrations: Identification of DDX5-ETV4 Fusion Protein in Prostate Cancer. Cancer Research, 2008, 68, 7629-7637.	0.9	139
28	New developments in existing WHO entities and evolving molecular concepts: The Genitourinary Pathology Society (GUPS) update on renal neoplasia. Modern Pathology, 2021, 34, 1392-1424.	5.5	138
29	HER2 and EGFR Overexpression Support Metastatic Progression of Prostate Cancer to Bone. Cancer Research, 2017, 77, 74-85.	0.9	137
30	Variant (divergent) histologic differentiation in urothelial carcinoma is under-recognized in community practice: Impact of mandatory central pathology review at a large referral hospital. Urologic Oncology: Seminars and Original Investigations, 2013, 31, 1650-1655.	1.6	136
31	Dickkopfâ€l expression increases early in prostate cancer development and decreases during progression from primary tumor to metastasis. Prostate, 2008, 68, 1396-1404.	2.3	127
32	Carcinoma of the Collecting Ducts of Bellini and Renal Medullary Carcinoma. American Journal of Surgical Pathology, 2012, 36, 1265-1278.	3.7	127
33	Postatrophic Hyperplasia of the Prostate Gland. American Journal of Pathology, 2001, 158, 1767-1773.	3.8	125
34	A Working Group Classification of Focal Prostate Atrophy Lesions. American Journal of Surgical Pathology, 2006, 30, 1281-1291.	3.7	123
35	Renal Tubulocystic Carcinoma Is Closely Related to Papillary Renal Cell Carcinoma: Implications for Pathologic Classification. American Journal of Surgical Pathology, 2009, 33, 1840-1849.	3.7	121
36	Novel, emerging and provisional renal entities: The Genitourinary Pathology Society (GUPS) update on renal neoplasia. Modern Pathology, 2021, 34, 1167-1184.	5.5	118

#	Article	IF	CITATIONS
37	Interobserver Reproducibility in the Diagnosis of Invasive Micropapillary Carcinoma of the Urinary Tract Among Urologic Pathologists. American Journal of Surgical Pathology, 2010, 34, 1367-1376.	3.7	111
38	CXCL12 overexpression and secretion by aging fibroblasts enhance human prostate epithelial proliferation in vitro. Aging Cell, 2005, 4, 291-298.	6.7	110
39	Integrative Analysis of Genomic Aberrations Associated with Prostate Cancer Progression. Cancer Research, 2007, 67, 8229-8239.	0.9	103
40	Utility of PTEN and ERG Immunostaining for Distinguishing High-grade PIN From Intraductal Carcinoma of the Prostate on Needle Biopsy. American Journal of Surgical Pathology, 2015, 39, 169-178.	3.7	99
41	Renal Cell Carcinomas With Papillary Architecture and Clear Cell Components. American Journal of Surgical Pathology, 2008, 32, 1780-1786.	3.7	98
42	Registration Methodology for Histological Sections and In Vivo Imaging of Human Prostate. Academic Radiology, 2008, 15, 1027-1039.	2.5	92
43	Characterization of ETS gene aberrations in select histologic variants of prostate carcinoma. Modern Pathology, 2009, 22, 1176-1185.	5.5	91
44	ETS Gene Aberrations in Atypical Cribriform Lesions of the Prostate. American Journal of Surgical Pathology, 2010, 34, 478-485.	3.7	91
45	Lymphoepithelioma-like Carcinoma of the Urinary Bladder. American Journal of Surgical Pathology, 2011, 35, 474-483.	3.7	88
46	Detection of Aggressive Primary Prostate Cancer with <sup>11</sup> C-Choline PET/CT Using Multimodality Fusion Techniques. Journal of Nuclear Medicine, 2009, 50, 1585-1593.	5.0	86
47	Prostate-Specific Antigen, High-Molecular-Weight Cytokeratin (Clone 34βE12), and/or p63. American Journal of Clinical Pathology, 2006, 125, 675-681.	0.7	85
48	Usefulness of Basal Cell Cocktail (34βE12 + p63) in the Diagnosis of Atypical Prostate Glandular Proliferations. American Journal of Clinical Pathology, 2004, 122, 517-523.	0.7	82
49	Atypical Cribriform Lesions of the Prostate: Relationship to Prostatic Carcinoma and Implication for Diagnosis in Prostate Biopsies. American Journal of Surgical Pathology, 2010, 34, 470-477.	3.7	80
50	MRI for Preoperative Staging of Renal Cell Carcinoma Using the 1997 TNM Classification:Comparison with Surgical and Pathologic Staging. American Journal of Roentgenology, 2004, 182, 217-225.	2.2	77
51	Detection and expression of human BK virus sequences in neoplastic prostate tissues. Oncogene, 2004, 23, 7031-7046.	5.9	76
52	Epidermal growth factor receptor (ErbB1) expression in prostate cancer progression: Correlation with androgen independence. Prostate, 2006, 66, 1437-1444.	2.3	74
53	Introducing Parametric Fusion PET/MRI of Primary Prostate Cancer. Journal of Nuclear Medicine, 2012, 53, 546-551.	5.0	72
54	Characterization of Bone Metastases from Rapid Autopsies of Prostate Cancer Patients. Clinical Cancer Research, 2011, 17, 3924-3932.	7.0	69

Rajal B Shah

#	Article	IF	CITATIONS
55	Elevated α-Methylacyl-CoA Racemase Enzymatic Activity in Prostate Cancer. American Journal of Pathology, 2004, 164, 787-793.	3.8	68
56	Diagnosis of "Poorly Formed Glands―Gleason Pattern 4 Prostatic Adenocarcinoma on Needle Biopsy. American Journal of Surgical Pathology, 2015, 39, 1331-1339.	3.7	67
57	"Renal Cell Carcinoma With Leiomyomatous Stroma―Harbor Somatic Mutations of TSC1, TSC2, MTOR, and/or ELOC (TCEB1): Clinicopathologic and Molecular Characterization of 18 Sporadic Tumors Supports a Distinct Entity. American Journal of Surgical Pathology, 2020, 44, 571-581.	3.7	67
58	Diagnostic Usefulness of Monoclonal Antibody P504S in the Workup of Atypical Prostatic Glandular Proliferations. American Journal of Clinical Pathology, 2003, 120, 737-745.	0.7	64
59	p63, CK7, PAX8 and INIâ€1: an optimal immunohistochemical panel to distinguish poorly differentiated urothelial cell carcinoma from highâ€grade tumours of the renal collecting system. Histopathology, 2012, 60, 597-608.	2.9	63
60	Utility of cytokeratin 20 and Ki-67 as markers of urothelial dysplasia. Pathology International, 2005, 55, 248-254.	1.3	60
61	Cluster analysis of immunohistochemical profiles delineates CK7, vimentin, S100A1 and Câ€kit (CD117) as an optimal panel in the differential diagnosis of renal oncocytoma from its mimics. Histopathology, 2011, 58, 169-179.	2.9	51
62	The Discovery of Common Recurrent Transmembrane Protease Serine 2 (TMPRSS2)-Erythroblastosis Virus E26 Transforming Sequence (ETS) Gene Fusions in Prostate Cancer. Advances in Anatomic Pathology, 2009, 16, 145-153.	4.3	47
63	Heterogeneity of PTEN and ERG expression in prostate cancer on core needle biopsies: implications for cancer risk stratification and biomarker sampling. Human Pathology, 2015, 46, 698-706.	2.0	45
64	Primary Anal Canal Syphilis in Men: The Clinicopathologic Spectrum of an Easily Overlooked Diagnosis. Archives of Pathology and Laboratory Medicine, 2015, 139, 1156-1160.	2.5	45
65	Benign prostatic glands at surgical margins of radical prostatectomy specimens: frequency and associated risk factors. Urology, 2000, 56, 721-725.	1.0	44
66	Atypical Cribriform Lesions of the Prostate. Advances in Anatomic Pathology, 2012, 19, 270-278.	4.3	44
67	Clinical Applications of Novel ERG Immunohistochemistry in Prostate Cancer Diagnosis and Management. Advances in Anatomic Pathology, 2013, 20, 117-124.	4.3	44
68	Diagnosis of Gleason Pattern 5 Prostate Adenocarcinoma on Core Needle Biopsy. American Journal of Surgical Pathology, 2015, 39, 1242-1249.	3.7	43
69	The diagnostic use of ERG in resolving an "atypical glands suspicious for cancer―diagnosis in prostate biopsies beyond that provided by basal cell and α-methylacyl-CoA-racemase markers. Human Pathology, 2013, 44, 786-794.	2.0	42
70	Intraductal carcinoma of the prostate: interobserver reproducibility survey of 39 urologic pathologists. Annals of Diagnostic Pathology, 2014, 18, 333-342.	1.3	41
71	Whole Transcriptome Amplification for Gene Expression Profiling and Development of Molecular Archives. Neoplasia, 2006, 8, 153-162.	5.3	40
72	Current Perspectives on the Gleason Grading of Prostate Cancer. Archives of Pathology and Laboratory Medicine, 2009, 133, 1810-1816.	2.5	40

#	Article	IF	CITATIONS
73	Partial Atrophy in Prostate Needle Biopsies: A Detailed Analysis of Its Morphology, Immunophenotype, and Cellular Kinetics. American Journal of Surgical Pathology, 2008, 32, 58-64.	3.7	39
74	Atypical intraductal proliferation and intraductal carcinoma of the prostate on core needle biopsy: a comparative clinicopathological and molecular study with a proposal to expand the morphological spectrum of intraductal carcinoma. Histopathology, 2017, 71, 693-702.	2.9	39
75	Atypical Intraductal Cribriform Proliferations of the Prostate Exhibit Similar Molecular and Clinicopathologic Characteristics as Intraductal Carcinoma of the Prostate. American Journal of Surgical Pathology, 2017, 41, 550-556.	3.7	38
76	Percent Positive Biopsy Cores as a Prognostic Factor for Prostate Cancer Treated with External Beam Radiation. Urology, 2007, 69, 936-940.	1.0	37
77	Laparoscopic and Open Surgical Nephrectomy for Xanthogranulomatous Pyelonephritis. Journal of Endourology, 2005, 19, 813-817.	2.1	35
78	PTEN loss in prostatic adenocarcinoma correlates with specific adverse histologic features (intraductal carcinoma, cribriform Gleason pattern 4 and stromogenic carcinoma). Prostate, 2019, 79, 1267-1273.	2.3	34
79	Validation of Automatic Target Volume Definition as Demonstrated for 11C-Choline PET/CT of Human Prostate Cancer Using Multi-modality Fusion Techniques. Academic Radiology, 2010, 17, 614-623.	2.5	33
80	Image-guided biopsy in the evaluation of renal mass lesions in contemporary urological practice: indications, adequacy, clinical impact, and limitations of the pathological diagnosis. Human Pathology, 2005, 36, 1309-15.	2.0	31
81	Reporting Practices and Resource Utilization in the Era of Intraductal Carcinoma of the Prostate. American Journal of Surgical Pathology, 2020, 44, 673-680.	3.7	31
82	Usefulness of Basal Cell Cocktail (p63+34bE12) in the Diagnosis of Atypical Prostate Glandular Proliferations. American Journal of Clinical Pathology, 2004, 122, 517-523.	0.7	29
83	Recent advances in prostate cancer pathology: Gleason grading and beyond. Pathology International, 2016, 66, 260-272.	1.3	28
84	In vivo visualization of metastatic prostate cancer and quantitation of disease progression in immunocompromised mice. Cancer Biology and Therapy, 2003, 2, 656-60.	3.4	28
85	Evaluation of the prostate peripheral zone/capsule in patients undergoing radical cystoprostatectomy: Defining risk with prostate capsule sparing cystectomy. Urologic Oncology: Seminars and Original Investigations, 2007, 25, 460-464.	1.6	26
86	HLA-DR and HLA-DQ polymorphism in human thyroglobulin-induced autoimmune thyroiditis: DR3 and DQ8 transgenic mice are susceptible. Human Immunology, 2002, 63, 301-310.	2.4	25
87	The Genitourinary Pathology Society Update on Classification and Grading of Flat and Papillary Urothelial Neoplasia With New Reporting Recommendations and Approach to Lesions With Mixed and Early Patterns of Neoplasia. Advances in Anatomic Pathology, 2021, 28, 179-195.	4.3	23
88	Atypical intraductal proliferation detected in prostate needle biopsy is a marker of unsampled intraductal carcinoma and other adverse pathological features: a prospective clinicopathological study of 62 cases with emphasis on pathological outcomes. Histopathology, 2019, 75, 346-353.	2.9	22
89	The Genitourinary Pathology Society Update on Classification of Variant Histologies, T1 Substaging, Molecular Taxonomy, and Immunotherapy and PD-L1 Testing Implications of Urothelial Cancers. Advances in Anatomic Pathology, 2021, 28, 196-208.	4.3	20
90	H2-E transgenic class II-negative mice can distinguish self from nonself in susceptibility to heterologous thyroglobulins in autoimmune thyroiditis. Immunogenetics, 1999, 50, 22-30.	2.4	17

#	Article	IF	CITATIONS
91	Localized Amyloidosis of the Upper Urinary Tract: A Case Series of Three Patients Managed with Reconstructive Surgery or Surveillance. Journal of Endourology, 2010, 24, 641-644.	2.1	17
92	ls residual neurovascular tissue on prostatectomy specimens associated with surgeon intent at nerve-sparing and postoperative quality of life measures?. Urologic Oncology: Seminars and Original Investigations, 2010, 28, 487-491.	1.6	17
93	Renal Cell Carcinoma With Fibromyomatous Stroma—The Whole Story. Advances in Anatomic Pathology, 2022, 29, 168-177.	4.3	17
94	Renal Metastasis from Hurthle Cell Thyroid Carcinoma and Its Evaluation with Hybrid Imaging. Thyroid, 2010, 20, 429-433.	4.5	16
95	Improvement of diagnostic agreement among pathologists in resolving an "atypical glands suspicious for cancer―diagnosis in prostate biopsies using a novel "Disease-Focused Diagnostic Review―quality improvement process. Human Pathology, 2016, 56, 155-162.	2.0	16
96	Adenocarcinoma of the prostate with Gleason pattern 5 on core biopsy: frequency of diagnosis, morphologic subpatterns, and relation to pattern distribution based on the modified Gleason grading system. Human Pathology, 2014, 45, 2263-2269.	2.0	15
97	Urothelial Carcinomas With Trophoblastic Differentiation, Including Choriocarcinoma. American Journal of Surgical Pathology, 2020, 44, 1322-1330.	3.7	15
98	<scp>GATA</scp> 3 expression in benign prostate glands with radiation atypia: a diagnostic pitfall. Histopathology, 2017, 71, 150-155.	2.9	13
99	Integrating Biomedical Knowledge to Model Pathways of Prostate Cancer Progression. Cell Cycle, 2007, 6, 1177-1187.	2.6	12
100	Gleason Grade Group Concordance between Preoperative Targeted Biopsy and Radical Prostatectomy Histopathologic Analysis: A Comparison Between In-Bore MRI-guided and MRI–Transrectal US Fusion Prostate Biopsies. Radiology Imaging Cancer, 2021, 3, e200123.	1.6	12
101	The quality of surgical pathology care for men undergoing radical prostatectomy in the U.S Cancer, 2007, 109, 2445-2453.	4.1	11
102	Diagnostic Usefulness of Monoclonal Antibody P504S in the Workup of Atypical Prostatic Glandular Proliferations. American Journal of Clinical Pathology, 2003, 120, 737-745.	0.7	9
103	Histologic and Histochemical Characterization of Seminal Vesicle Intraluminal Secretions. Archives of Pathology and Laboratory Medicine, 2001, 125, 141-145.	2.5	9
104	Signaling mechanisms coupled to CXCL12/CXCR4-mediated cellular proliferation are PTEN-dependent. American Journal of Clinical and Experimental Urology, 2015, 3, 91-9.	0.4	9
105	Nephron-Sparing Diagnosis and Management of Renal Keratinizing Desquamative Squamous Metaplasia. Journal of Endourology, 2009, 23, 51-56.	2.1	8
106	ERG overexpression and multifocality predict prostate cancer in subsequent biopsy for patients with high-grade prostatic intraepithelial neoplasia. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 120.e1-120.e7.	1.6	8
107	Protein Kinase N1 control of androgen-responsive serum response factor action provides rationale for novel prostate cancer treatment strategy. Oncogene, 2019, 38, 4496-4511.	5.9	8
108	Significant reduction of indeterminate (atypical) diagnosis after implementation of The Paris System for Reporting Urinary Cytology: A singleâ€institution study of more than 27,000 cases. Cancer Cytopathology, 2021, 129, 114-120.	2.4	8

#	ARTICLE	IF	CITATIONS
109	Tomlins et al. reply. Nature, 2009, 457, E2-E3.	27.8	6
110	Variable Penetrance of a Consensus Classification Scheme for Renal Cell Carcinoma. Urology, 2007, 69, 452-456.	1.0	5
111	2019 Gleason grading recommendations from ISUP and GUPS: broadly concordant but with significant differences. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2021, 478, 813-815.	2.8	5
112	Isolated recurrent renal cell carcinoma metastatic to the bladder. Journal of the National Medical Association, 2002, 94, 912-4.	0.8	5
113	Diagnosis of "cribriform" prostatic adenocarcinoma: an interobserver reproducibility study among urologic pathologists with recommendations. American Journal of Cancer Research, 2021, 11, 3990-4001.	1.4	4
114	Enrichment of "Cribriform―morphologies (intraductal and cribriform adenocarcinoma) and genomic alterations in radiorecurrent prostate cancer. Modern Pathology, 0, , .	5.5	3
115	Benign Diseases and Neoplasms of the Penis. Surgical Pathology Clinics, 2009, 2, 161-197.	1.7	2
116	Reply to †Lowâ€grade intraductal carcinoma of the prostate: an idea whose time has not yet come': evidenceâ€based medicine suggests that the time is now. Histopathology, 2017, 71, 839-840.	2.9	2
117	Molecular Biology of Prostate Cancer and Role of Genomic Testing in Diagnosis and Prognosis of Prostate Cancer. , 2019, , 171-180.		0
118	Immunohistochemistry in Prostate Biopsy Evaluation. , 2019, , 33-43.		0
119	Contemporary Approach to Cleason Grading of Prostate Cancer. , 2019, , 45-67.		0
120	Benign Mimics of Prostate Carcinoma. , 2019, , 97-125.		0
121	Intraductal Carcinoma of the Prostate (IDC-P) and Atypical Intraductal Proliferation (AIP). , 2019, , 127-132.		0
122	New Molecular Markers of Diagnosis and Prognosis in Prostate Cancer. , 2015, , 123-143.		0